// App-Quantinova.ai

e15027 : Early reduction in circulating tumor DNA (ctDNA) and survival in gastric cancer patients (pts) treated with durvalumab (D), tremelimumab (T), or durvalumab in combination with tremelimumab (D+T).

Researchers

Presenter

  • Philip Z. Brohawn

Principal Investigators

  • Brandon W. Higgs

  • Michael Kuziora

  • Judson Englert

  • Koustubh Ranade

Medical Centers

  • MedImmune, Gaithersburg, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating DNA

Drug/Treatment

  • Ticilimumab

  • Durvalumab

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT02340975

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved